Roche signs molecular glue discovery deal with China's Defand Therapeutics
- STAT reports Roche has signed a drug discovery deal with Chinese biotech Defand Therapeutics focused on molecular glue medicines.
- Only the public lede of the STAT+ article could be read, so financial terms and targets are unverified here.
💡 Points
Roche keeps adding molecular glue partners rather than betting on one platform, and sourcing from Chinese biotechs fits the wider licensing trend. Without upfront and milestone figures I'd treat this as a discovery-stage option play, with the real signal being which targets and how many are named.
STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines ↗